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It is well known that infection is one of the major causes of morbidity and mortality in rheumatic 
disease patients treated with high-dose glucocorticoids,  especially in the early phase after achieve-
ment of disease remission.  The aim of this study was to identify the risk factors for infection,  with 
a focus on the dose of glucocorticoids administered,  following the achievement of disease remission 
in rheumatic diseases patients.  We retrospectively analyzed the medical records of rheumatic disease 
patients who had been treated with glucocorticoids.  The primary endpoint was the incidence rate of 
infection during a period from 1 to 2 months after the commencement of treatment.  From April 2006 
to March 2010,  19 of 92 patients suﬀered from infection during the observation period.  Age≧65 yrs,  
presence of interstitial pneumonia,  diagnosis of systemic vasculitis and serum creatinine level≧
2.0mg/dl were found to be univariate predictors for infection.   However,  only the presence of inter-
stitial pneumonia was an independent risk factor for infection (HR＝4.50,  95ｵCI＝1.65 to 14.44) by 
the Cox proportional hazard model.  Even after achievement of clinical remission,  careful observa-
tion is needed for patients with interstitial pneumonia,  more so than for those receiving high-dose 
glucocorticoids.
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he overall survival of patients with rheumatic 
diseases has improved,  but infection is still one 
of the major causes of morbidity and mortality in these 
patients [1-4].  Previous studies have shown that 
infection-induced complications occurred in 14-45ｵ 
of patients with systemic lupus erythematosus (SLE) 
[5,  6],  and a review of 30 studies showed that the 
median rate of mortality due to infection was 5.2ｵ 
(range,  1.2-36ｵ) [7].  It has also been reported that 
the infection-related mortality rate in patients with 
rheumatoid arthritis (RA) was signiﬁcantly higher than 
that in an age- and sex-matched healthy population 
[7-9].
　 The high rate of infectious complications in 
patients with rheumatic diseases is generally attrib-
uted to the activity of primary diseases and impair-
ment of immune function due to the inﬂuence of 
immunosuppressive therapy [10].  The use of high-
dose glucocorticoids and/or other immunosupressants 
increases the risk of infectious complications in 
patients with rheumatic diseases [5,  11-17].  Yuhara 
et al.  reported that the average duration between the 
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commencement of treatment with glucocorticoids and 
the occurrence of infections was 52±44 (mean ± SD) 
days [18].  Therefore,  careful observation and appro-
priate examinations for early detection of infection-
related complications in patients with rheumatic dis-
eases in the early phase after achievement of disease 
remission are clinically important.
　 The aim of the present study was to identify the 
risk factors for infection-induced complications,  with 
a focus on the dose of glucocorticoids administered,  
following achievement of disease remission in patients 
with rheumatic diseases.
Patients and Methods
　 Patients. We retrospectively reviewed the 
medical records of adult patients with rheumatic dis-
ease who were admitted to Okayama University 
Hospital during the period from April 2006 to March 
2010.  The diagnostic criteria used for the patients 
included the 1997 revised criteria of the American 
College of Rheumatology (ACR) for SLE,  the criteria 
of the ACR and Chapel Hill Consensus Conference 
(CHCC) for systemic vasculitis,  the criteria of the 
ACR for RA,  and the criteria of Bohan and Peter for 
polymyositis/dermatomyositis.  Patients who had been 
treated with glucocorticoids at doses over 30mg/day 
and/or other immunosupressants and who had achieved 
remission were enrolled in this study.  Remission was 
deﬁned as the state of absence of disease activity,  
including physical examination,  radiologic study and 
biomarker levels from a blood or urine test at one 
month after the commencement of treatment.  Since the 
purpose of our study was to investigate predictors for 
infection-related complications in the early phase after 
achievement of disease remission,  patients who did not 
achieve remission and patients who received treatment 
with glucocorticoids in other hospitals before being 
transferred to our hospital were excluded from the 
study.
　 Risk factors for infection. Clinical variables 
for analysis included age,  sex,  body weight,  smoking 
habit,  Charlson score [19],  vital organ involvement 
(heart,  kidney and central nervous system) at baseline,  
presence of interstitial pneumonia at baseline,  pres-
ence of diabetes mellitus at baseline,  serum albumin 
level,  serum creatinine level,  serum IgG level,  use of 
methylprednisolone pulse,  doses of glucocorticoids,  
use of immunosupressants,  and prophylactic use of 
sulfamethoxazole-trimethoprim.  Data were extracted 
from the hospital charts of patients and recorded on 
study forms.
　 Study endpoint and deﬁnition of infection.
The primary endpoint of the present study was the 
incidence rate of infection during a period of one 
month after achievement of disease remission (1 to 2 
months after treatment began).  Infection was con-
ﬁrmed by the existence of supportive clinical features,  
laboratory ﬁndings,  positive cultures and radio-
graphic evidence [12,  18].  When causal organisms 
were not identiﬁed,  the diagnosis of infection was 
made on the basis of clinical ﬁndings in combination 
with improvement following antimicrobial therapy.  
Cytomegalovirus (CMV) infection was deﬁned in the 
study as either detection of CMV pp65 antigenaemia 
in blood samples or compatible tissue biopsy ﬁndings.  
We deﬁned an antigenaemia count of 10 per 1×105 
PMNs as a cut-oﬀ to start prophylactic anti-viral 
therapy before the infection became too severe [20].
　 Statistical analysis. Statistical analysis was 
performed with JMP® 7 (SAS Institute Inc,  Cary,  
NC,  USA).  Potential predictors of infection including 
variables with a possible relation to infection were 
studied by life table analysis using the Kaplan-Meier 
method.  Survival (cumulative probability without 
infection) curves with the presence or absence of 
variables with a possible relation to infection were 
compared using the non-parametric log-rank test (uni-
variate model).  In order to identify independent pre-
dictors of infection,  all variables with p＜0.20 in the 
univariate analysis were entered into multivariate 
analysis using the Cox proportional hazard model.  The 
hazard ratio (HR) and 95ｵ conﬁdence intervals (CI) 
were calculated for each of the factors studied.  
Statistical signiﬁcance was deﬁned as a two-tailed p 
-value of less than 0.05.
Results
　 Study population. In the period from April 
2006 to March 2010,  944 patients were admitted to 
Okayama University Hospital for treatment of active 
rheumatic diseases.  Among them,  144 patients were 
treated with glucocorticoids at initial doses of over 
30mg/day.  Of those patients,  92 were included in the 
cohort at the time of this study (Table 1).  The 92 
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patients were comprised of 28 men (30.5ｵ) and 64 
women (69.5ｵ).  The mean (SD) age at diagnosis was 
57.5 (19.4) years.  The mean (SD) dose of glucocorti-
coids at the commencement of treatment was 41.5 
(10.7) mg/dl.  The mean (SD) dose of glucocorticoids 
at the time of achievement of disease remission (the 
starting point of our study) was 34.1 (9.2) mg/dl.  The 
percentage of patients with each type of rheumatic 
disease is shown in Table 2.  Systemic vasculitis was 
the most frequent rheumatic disease in our study.
　 Infectious complications in the study popula-
tion. Nineteen patients (20.7ｵ) suﬀered from at 
least one infection and were admitted to the hospital 
during a one-month period after achievement of dis-
ease remission.  The localizations of infection are 
shown in Table 3.  CMV infection was the most fre-
quent infection in patients with rheumatic diseases in 
our study (10 of 19 patients),  and ganciclovir was 
administered to these 10 patients.  No patients died 
due to infections during the study period.
　 Univariate correlates of infection. The 
baseline of infected (or non-infected) patients with 
rheumatic diseases is shown in Table 4.  Risk factors 
for infection were studied by univariate (log-rank test) 
analysis.  Age≧65 yrs,  a diagnosis of systemic vascu-
litis,  the presence of interstitial pneumonia,  and 
serum creatinine level≧2.0mg/dl were found to be 
univariate predictors for infection.  Use of glucocorti-
coids and immunosupressants was not associated with 
infection during the study period.
　 Multivariate correlation of infection. All 
variables with p＜0.20 in the univariate analysis were 
entered into the multivariate Cox proportional hazard 
model,  and only the presence of interstitial pneumonia 
was an independent risk factor for predicting infection 
(HR＝4.50,  95ｵCI＝1.65 to 14.44) (Table 5).  The 
remaining variables,  including daily dose of glucocor-
ticoids,  were not associated with infection.
Discussion
　 Previous studies have shown that early mortality in 
patients with rheumatic diseases is predominantly 
related to the individual activity of disease progres-
sion,  vital organ involvement and infectious complica-
tion [21].  Noel et al.  reported that 35 (40ｵ) of 87 
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Table 1　 Patient proﬁle regarding rheumatic diseases in our study
Subjects n (%)
Sex (male/female) 28/64
Age,  median (SD),  yrs 57.5 (19.4)
Body height,  median (SD),  cm 155.9 (9.0)
Body weight,  median (SD),  kg 54.0 (12.3)
Mean dose of prednisolone at the commencement of treatment,  median (SD),  mg/day 41.7 (10.7)
Mean dose of prednisolone at the time of achievement of disease remission,  median (SD),  mg/day 34.1 (9.2)
Data are expressed as number and mean ± SD.
Table 2　 Disease proﬁle of the rheumatic diseases in our study
Diagnosed disease n (%)
Systemic vasculitis 35 (38.0%)
Systemic lupus erythematosus 29 (31.5%)
Polymyositis/Dermatomyositis 11 (12.0%)
Rheumatoid arthritis 4 (4.3%)
Sjogrenʼs syndrome 2 (2.2%) 
Henoch-Schonlein purpura 1 (1.1%)
Relapsing polychondritis 1 (1.1%)
Systemic sclerosis 1 (1.1%)
Adult-onset Stillʼs disease 1 (1.1%)
Others 7 (7.6%)
Data are expressed as number of patients (%).
Table 3　 Characteristics of infectious complications in patients 
with rheumatic diseases
Infection site n (%)
CMV viraemia 8 (42.1%)
Pulmonary 4 (21.1%)
Urinary tract 3 (15.8%)
CMV colitis 2 (10.5%)
Facial herpes zoster 1 (5.3%)
Herpesvirus ulceration of the cornea 1 (5.3%)
CMV,  cytomegalovirus.
Data are expressed as number of infectious episodes (%).
patients with SLE had at least one infectious episode 
during a mean period of 9.4 years [5,  6].  Although 
our observation period was short,  the rate of infec-
tious complications in the present study was 20.7ｵ 
(19 out of 92 patients).  This high frequency of infec-
tion might be associated with the presence of CMV 
viraemia diagnosed on the basis of positive CMV 
antigenaemia,  which is the most frequent infection in 
patients with rheumatic diseases.
　 CMV infection is a major cause of morbidity and 
mortality in immunocompromised hosts [20].  
Prophylactic administration of ganciclovir for CMV 
antigenaemia-positive patients is an eﬀective thera-
peutic strategy [22-25].  In addition,  Takizawa et al.  
suggested that the threshold of the antigenaemia count 
is 5.6 per 1×105 PMNs,  which predicts that patients 
are at a higher risk of being symptomatic,  leading to 
a lethal condition [20].  Therefore,  we continuously 
investigated CMV pp65 antigenaemia in blood samples 
for all of the patients enrolled in our study.  In the 
present study,  we diagnosed CMV infection by a 
threshold (or cut-oﬀ value) of an antigenaemia count of 
332 Acta Med.  Okayama　Vol.  65,  No.  5Matsumoto et al.
Table 4　 Univariate analysis of potential risk factors for infection in our cohort of 92 patients with rheumatic diseases
Infected Non-infected
Variables n＝19 (%) n＝73 (%) HR (95%CI) P-value
Age≧65 yrs 15 (78.9) 30 (41.1) 4.52 (1.64-15.86) 0.0027※
Sex (woman) 15 (78.9) 49 (67.1) 1.74 (0.63-6.11) 0.30
Smoking (yes)  5 (26.3) 19 (26.0) 1.12 (0.35-3.08) 0.84
Charlson score≧1  8 (42.1) 22 (30.1) 1.64 (0.63-4.04) 0.30
Diagnosis of systemic vasculitis (yes) 11 (57.1) 24 (32.9) 2.56 (1.04-6.61) 0.042※
Diagnosis of systemic lupus erythematosus (yes)  3 (15.8) 26 (35.6) 0.37 (0.085-1.10) 0.077
Presence of interstitial pneumonia (yes) 14 (73.7) 21 (28.8) 5.35 (2.04-16.55) 0.00050※
Presence of diabetes mellitus (yes)  9 (47.4) 21 (28.8) 2.05 (0.81-5.08) 0.13
Serum creatinine level≧2.0mg/dl  7 (36.8)  9 (12.3) 3.10 (1.15-7.71) 0.027※
Serum albumin level＜3.0mg/dl 11 (57.1) 25 (34.2) 2.32 (0.94-5.99) 0.068
Serum IgG level＜870mg/dl  9 (47.4) 39 (53.4) 0.58 (0.031-3.07) 0.58
Use of methylprednisolone pulse (yes) 10 (52.6) 32 (43.8) 1.44 (0.58-3.63) 0.43
Dose of prednisolone≧1mg/kg/day at the commencement of 
treatment
11 (57.1) 53 (72.6) 0.76 (0.18-2.29) 0.65
Dose of prednisolone≧1mg/kg/day at the point of the achieve-
ment of disease remission
 3 (15.8) 29 (39.7) 1.26 (0.070-6.12) 0.83
Use of immunosupressants (yes) 11 (57.1) 34 (46.6) 1.46 (0.59-3.78) 0.41
Prophylactic use of sulfamethoxazole-trimethoprim (yes)  8 (42.1) 41 (56.2) 0.61 (0.15-4.04) 0.55
HR,  hazard ratio; CI,  conﬁdence interval.
Data are expressed as variables followed by number of patients,  hazard ratio,  95% conﬁdence interval and p-value.
※p＜0.05
Table 5　 Multivariate analysis (Cox proportional hazard model) for variables predicting infection in our cohort of 92 patients with rheu-
matic diseases
Variables HR (95%CI) P-value
Age≧65yrs 2.35 (0.77-8.73) 0.14
Presence of interstitial pneumonia 4.50 (1.65-14.44) 0.0028※
With heart involvement 1.24 (0.25-4.71) 0.77
Diagnosis of systemic vasculitis 1.41 (0.39-5.68) 0.61
Diagnosis of systemic lupus erythematosus 0.90 (0.17-4.10) 0.89
Presence of diabetes mellitus 1.09 (0.37-3.17) 0.88
Serum creatinine level≧2.0mg/dl 1.58 (0.50-4.65) 0.42
Serum albumin level＜3.0mg/dl 1.75 (0.67-4.83) 0.25
HR,  hazard ratio; CI,  conﬁdence interval.
Data are expressed as variables followed by hazard ratio,  95% conﬁdence interval and p-value.
※p＜0.05
over 10 per 1×105 PMNs.  Our results indicated that 
patients with rheumatic diseases are at high risk for 
occult CMV infection even without any symptoms.  
The high frequency of positive CMV antigenaemia also 
leads to high susceptibility to various infections.
　 Various risk factors for infection,  including 
decreasing renal function [26-29],  hypoalbuminemia 
[30-33] and diabetes mellitus [34-37],  have been 
reported.  High-dose glucocorticoids have been 
reported to be the most critical risk factor for pro-
gression of infections [5,  38].  However,  unlike in 
previous studies,  infectious complications in the early 
phase after achievement of disease remission were not 
statistically associated with decreasing renal function,  
hypoalbuminemia,  presence of diabetes mellitus or 
even the daily dose of glucocorticoids in the present 
study.
　 In Japan,  considering the infectious complications 
of glucocorticoids after discharge,  even patients who 
have achieved remission often remain in hospital until 
the daily dose of prednisolone is reduced to less than 
30mg.  This traditional practice is generally accepted 
without clear evidence in Japan,  but there is contro-
versy over this practice [39].  However,  our results 
indicated that the daily dose of glucocorticoids should 
not be the only factor for deciding when to discharge 
patients who have been treated with glucocorticoids 
and have achieved clinical remission.
　 Our multivariate analysis also showed that the 
presence of interstitial pneumonia is an approximately 
ﬁve-fold higher risk factor for infectious complica-
tions during the early period after achievement of 
disease remission.  There has been no previous report 
regarding the association between the presence of 
interstitial pneumonia and infection in patients with 
rheumatic diseases.  Our results also suggest that 
careful observation of patients with interstitial pneu-
monia is needed to reduce infection-related mortality,  
even after achievement of clinical remission.
　 This is the ﬁrst report regarding clinical predic-
tors of infection during the early phase after achieve-
ment of disease remission in patients with rheumatic 
diseases.  Our ﬁndings indicate that careful observa-
tion and/or examination are needed,  particularly for 
patients with interstitial pneumonia; such patients 
need more monitoring than those receiving high-dose 
glucocorticoids.  Therefore,  the daily dose of gluco-
corticoids does not appear to be a reliable factor for 
determining when to discharge patients.  This study 
had several limitations.  First,  it was a retrospective 
study with selection bias and incomplete medical 
records.  Second,  the daily dose of glucocorticoids 
was set to 30mg,  and this dose could be changed.  A 
future prospective study with a larger number of 
rheumatic disease patients is needed to conﬁrm our 
ﬁndings and to determine the ideal and cost-beneﬁcial 
duration for the hospitalization of patients with rheu-
matic diseases who are receiving high-dose glucocorti-
coids.
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